Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Year's New Drugs & Biologics - 2009.

Drug news & perspectives·2010

Same author

Overcoming the obstacles in the pharma/biotech industry: 2009 update.

Drug news & perspectives·2010

Same author

The year's new drugs & biologics - 2008.

Drug news & perspectives·2009

Same author

Overcoming the obstacles in the pharma/biotech industry: 2008 update.

Drug news & perspectives·2009

Same author

The year's new drugs.

Drug news & perspectives·2006

Same author

Filling the gaps: osteogenesis imperfecta.

Drug news & perspectives·2005

Same journal

New drug discovery and development in India.

Drug news & perspectives·2013

Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010

Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010

Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010

Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010

Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Promoting, improving and accelerating the drug development and approval processes.

¹ann.graul@thomsonreuters.com

Drug News & Perspectives

|February 12, 2009

Summary

This summary is machine-generated.

Regulatory agencies are collaborating with the pharmaceutical industry to accelerate drug development. Initiatives like the Orphan Drug Act and Quality by Design aim to improve R&D productivity and reduce attrition for new therapies.

More Related Videos

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

Related Experiment Videos

Last Updated: Jun 25, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

Area of Science:

Pharmacology and Drug Development
Regulatory Science
Biotechnology Innovation

Background:

Pharmaceutical and biotech companies employ R&D productivity strategies.
Regulatory agencies are increasingly partnering with industry.
Historical context includes the U.S. FDA's Orphan Drug Act (26 years ago).

Purpose of the Study:

To outline regulatory initiatives promoting drug development.
To highlight collaborative efforts between agencies and industry.
To explain programs designed to accelerate new drug approval.

Main Methods:

Review of regulatory programs and policies.
Analysis of initiatives promoting R&D productivity.
Examination of strategies to reduce attrition in drug development.

Main Results:

Agencies have introduced programs to foster research in rare diseases.
Fast-track development and priority review vouchers incentivize research.
Phase 0/microdosing and Quality by Design aim to streamline processes.

Conclusions:

Regulatory agencies actively support and accelerate drug development.
Collaborative programs aim to improve R&D efficiency.
Initiatives focus on addressing unmet medical needs and reducing development failures.